Literature DB >> 29578474

Relationship of hematologic markers with IL-17 and IL-1 beta in patients with rheumatoid arthritis.

S Sağ1, M S Sağ1, I Tekeoğlu1, A Kamanlı1, K Nas1, B A Acar2.   

Abstract

OBJECTIVES: In this study, we aimed to investigate the relationship of NLR (Neutrophil lymphocyte ratio), MPV (mean platelet volume), PDW (distribution width) rates in rheumatoid arthritis (RA) patients with IL-17 and IL-1 beta which are within the cytokines playing an important role in etiopathogenesis and activity of the disease. PATIENTS AND METHODS: Fifty-seven RA patients diagnosed according to RA classification criteria of ACR/EULAR 2010 and 37 controls were included into the study. WBC (white blood cell), NEU (neutrophil), PLT (platelet), LYM (lymphocyte) values in complete blood count received from routine blood examination of patients were recorded, and NLR, PLR (platelet lymphocyte ratio) rates were recorded. IL-17 and IL-1 beta were studies in serum samples. Disease activity of RA patients was evaluated with Disease Activity Score (DAS28). Age, gender, disease age, BMI (body mass index), medications used, co-morbid diseases, smoking of the patients were recorded.
RESULTS: Fifty-seven RA patients (46 (80.7%) females, 11 (19.3%) males), and 34 patients (24 (70.6% females and 10 (29.4) males) as a control group were involved. Demographic characteristics were similar between two groups, and statistically significant difference was not detected between patient and control groups in terms of gender, age, and BMI (p> 0.05). We found higher NLR, MPV, PDW, IL-17 values in RA patients compared to control group (p< 0.05). There was a positive correlation of NLR with DAS28, CRP. While erythrocyte sedimentation rate (ESR) had negative correlation with MPV and PDW, it had positive correlation with PLT. We found positive correlation of C-reactive protein (CRP) with NLR and PLT. We could not find correlation of IL-1 beta and IL-17 with hematologic markers.
CONCLUSION: In this study, we investigated the relationship of IL-17 and IL-1 beta which play an important role in pathogenesis of RA patients with the parameters analyzed in routine complete blood count, providing information about disease activity such as DAS 28, CRP, and ESR. We illuminated on an issue which has not discussed before by looking from a different angle. More extensive, follow-up studies are needed to emphasize the importance of these parameters and to reveal the relationship between cytokines during the follow-up of the disease activity.

Entities:  

Keywords:  IL-17; Rheumatoid arthritis; neutrophil lymphocyte ratio

Mesh:

Substances:

Year:  2018        PMID: 29578474     DOI: 10.3233/BMR-170903

Source DB:  PubMed          Journal:  J Back Musculoskelet Rehabil        ISSN: 1053-8127            Impact factor:   1.398


  4 in total

1.  Exploring the molecular mechanism of Sishen Decoction in the treatment of rheumatoid arthritis.

Authors:  Jiannan Zheng; Yeyu Zhao; Qing Qi; Mingli Gao; Jing Yu
Journal:  Ann Transl Med       Date:  2022-09

2.  Could IL-1β, IL-6, IFN-γ, and sP-selectin serum levels be considered as objective and quantifiable markers of rheumatoid arthritis severity and activity?

Authors:  Olga M Koper-Lenkiewicz; Ewa Gińdzieńska-Sieśkiewicz; Joanna Kamińska; Anna J Milewska; Otylia Kowal-Bielecka; Joanna Matowicka-Karna
Journal:  Reumatologia       Date:  2022-02-28

3.  Analysis of hematological parameters in rheumatoid arthritis patients receiving biological therapy: contribution to prevention of avoidable hematological complications.

Authors:  Jana Pereckova; Silvia Martiniakova; Juraj Payer; Martin Falk; Zdenko Killinger; Tomas Perecko
Journal:  EXCLI J       Date:  2022-03-08       Impact factor: 4.022

4.  Effect of chrono-moxibustion and its influence on circadian rhythm for rheumatoid arthritis: A study protocol for a randomized controlled trial.

Authors:  Mingfang Yu; Shenqiao Yang; Bailu Chen; Lu Gan; Xinling He; Aiyang Wang; Xiao Wu
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.